SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is trending as part of the broader meme coin market, with active community debate over whether it serves as a legitimate speculative asset or simply a humorous example of crypto volatility. Investors are closely monitoring its technical price levels and volume trends while comparing it to other established meme projects.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

DEGEN is trending as the community speculates on upcoming updates for the project's social-fi app and potential new exchange listings. Traders are closely watching key technical levels and bullish chart patterns while discussing the potential for a recovery following recent volume surges.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is gaining significant community traction as investors anticipate major exchange listings and positive momentum from Ethereum's evolving technical landscape. The community is actively discussing the platform's potential for cross-chain automation and is focused on holding through price volatility as they wait for increased market exposure.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is experiencing heightened investor scrutiny following a volatile earnings report that revealed a growing backlog of orders alongside revised financial results. While the community remains divided over the company's ability to scale smart cart deployments and manage long-term profitability, active discussions are focused on the impact of newly secured non-dilutive financing and the potential for retail media revenue to offset operational losses.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant retail attention as community members rally behind its AI-powered infrastructure and ongoing development, with many investors actively accumulating the token on dips. The discussion is heavily centered on its potential for long-term utility within the Base ecosystem and high-conviction sentiment regarding its growth trajectory as an AI-native DeFi project.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph (GRT) is attracting significant community attention as investors position themselves for an anticipated altcoin rally, driven by its status as essential decentralized data infrastructure for Web3 and AI applications. While some users express frustration over past price performance, many are actively accumulating tokens, citing recent technical developments and high-profile integrations as indicators of long-term utility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors react to volatility driven by fears of AI-based tools disrupting traditional financial advisory models and fee structures. Despite recent downward pressure, the community remains actively divided, with many traders debating whether to buy the dip based on long-term fundamentals or if legacy brokerages face a structural threat from emerging AI-native competitors.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is generating significant community buzz as a targeted vehicle for space infrastructure exposure, particularly due to its inclusion of private SpaceX shares. Traders are actively debating its potential as a momentum play, comparing it to other space-themed assets while monitoring its ability to capture upside from the broader aerospace sector and anticipated industry catalysts.

Monero

Monero is experiencing significant community attention as investors weigh its role as a premier privacy asset amidst a broader resurgence in the privacy coin sector. Discussions are heavily focused on its potential as a hedge against tightening financial surveillance and the evolving risks posed by emerging quantum computing threats.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is experiencing significant community buzz as holders and traders leverage the platform's expanding lending and borrowing protocols, while active discussions highlight its role in the Solana ecosystem alongside trending memecoins. The community is focused on the platform's liquidity and utility, with ongoing debate surrounding tokenomics and the impact of recent market volatility on its long-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING...

<ul class="summary-bullets"><li>The outbreak has been linked to at least six confirmed infections and three deaths, according to the WHO.</li><li>The Andes strain is one of the few hantavirus variants associated with limited person-to-person transmission.</li><li>MRNA, INO, NVAX, and SABS gained attention due to their respective vaccine and antibody programs for infectious diseases, including hantavirus research.</li></ul><p>A rare hantavirus outbreak with reported potential for person-to-person transmission reignited Wall Street's outbreak-response trade on Monday.&nbsp;</p><p><a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> rose 6%,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">U.S.-listed shares of NVAX</a> and&nbsp;<a href="https://stocktwits.com/symbol/SABS">SABS</a> climbed 2%, while&nbsp;<a href="https://stocktwits.com/symbol/INO">INO</a> jumped 12% in premarket trading after U.S. officials confirmed an evacuated American passenger tested positive for the Andes strain.&nbsp;</p><h2 class="st-heading-2"><strong>Cruise Ship Outbreak Reaches The U.S.</strong></h2><p>The outbreak aboard the Dutch-flagged MV Hondius moved closer to the U.S. over the weekend after the U.S. Department of Health and Human Services confirmed that one evacuated American passenger tested mildly positive for the Andes strain of hantavirus. A second passenger also developed mild symptoms. Both symptomatic passengers were transported in biocontainment units during the evacuation flight. The returning U.S. passengers are expected to undergo evaluation at specialized treatment centers in Nebraska.</p><p>The outbreak has drawn attention after multiple passengers became infected during the ship’s trip from Argentina to Europe. According to the World Health Organization (WHO), at least six infections from the outbreak have been confirmed, while three passengers have died.&nbsp;</p><p>The virus involved is the Andes strain of Hantavirus, one of the few variants associated with limited person-to-person transmission. Severe cases can lead to hantavirus pulmonary syndrome, a respiratory illness with high fatality rates. However, the public risk remains low since the virus does not spread as easily as influenza or COVID-19.</p><h2 class="st-heading-2"><strong>Moderna Flags Early Hantavirus Work&nbsp;</strong></h2><p>Moderna moved back into focus after confirming that it has ongoing early-stage research tied to hantavirus vaccines. The company said it has worked with the U.S. Army Medical Research Institute of Infectious Diseases on hantavirus research and is also collaborating with Korea University’s Vaccine Innovation Center on a potential vaccine program. Moderna noted that the work began before the recent cruise ship outbreak emerged.</p><p>“These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against emerging infectious diseases,” the company told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-05-08/moderna-hantavirus-efforts-underway-before-cruise-ship-outbreak">Bloomberg</a>. Investors have long viewed Moderna as one of the leading outbreak-response companies on the back of its mRNA platform, which also gained traction during the COVID-19 pandemic. The company also said its mRNA tech can potentially shorten vaccine development timelines during outbreaks compared with older manufacturing methods that can take months.</p><h2 class="st-heading-2"><strong>INO, SABS, NVAX Stocks Draw Attention</strong></h2><p>Inovio Pharmaceuticals also attracted attention due to its previous work on DNA vaccines targeting multiple hantavirus strains, including the Andes variant linked to the current outbreak. Several of the company’s earlier studies were supported by the U.S. National Institute of Allergy and Infectious Diseases and the U.S. Army. However, none of the programs advanced into commercial vaccines.</p><p>SAB Biotherapeutics remained in focus as well because of its earlier development of SAB-163, a broad hantavirus antibody therapy. Preclinical studies previously showed activity against multiple hantavirus strains, including Andes and Sin Nombre viruses.</p><p>Meanwhile, Novavax joined the rally as traders rotated back into companies related to infectious disease and outbreak-response platforms. Novavax’s protein-based vaccine and Matrix-M adjuvant platform have previously been used in programs involving COVID-19, malaria, Ebola, MERS and Zika.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About Vaccine Stocks?</strong></h2><p>On Stocktwits, retail sentiment for MRNA, SABS, INO, NVAX was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><p>MRNA has surged 123% over the past year, while SABS jumped 139% and NVAX gained 52%. In contrast, INO remains down 20% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/drts-stock-rises-early-us-brain-cancer-trial-results-today/cZX9xaTReWl">DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today&nbsp;</a></p>

The HV Hondius approaches the Port of Granadilla, carrying passengers possibly infected with hantavirus on board in Tenerife, Canary Islands on May 10, 2026. (Photo by Andres Gutierrez/Anadolu via Getty Images)

MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak 

The HHS confirmed that one American passenger evacuated from the MV Hondius cruise ship tested mildly positive for the Andes strain of hantavirus.

Equity

INOVIO to Participate in Upcoming Scientific Conferences

INOVIO to Participate in Upcoming Scientific Conferences INOVIO to Participate in Upcoming Scientific Conferences PR Newswire PLYMOUTH MEETING, Pa., May 8, 2026 PLYMOUTH MEETING, Pa., May 8, 2026...

<ul class="summary-bullets"><li>Trump said that the administration will release a full report on a Hantavirus on Friday.</li><li>The outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths, six confirmed infections and additional suspected cases.</li><li>Moderna drew attention due to its hantavirus vaccine partnership with Korea University.</li></ul><p>Shares of vaccine makers and biodefense companies rallied overnight on&nbsp;Friday&nbsp;after U.S. President Donald Trump addressed a deadly hantavirus outbreak aboard a cruise ship and promised a full update on the situation.</p><p>Overnight,&nbsp;<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions (EBS)</a> climbed 3%, while&nbsp;<a href="https://stocktwits.com/symbol/INO">Inovio Pharmaceuticals (INO)</a> and&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax (NVAX)</a> each gained 2% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> rose 1%.</p><h2 class="st-heading-2"><strong>Trump Promises Full Hantavirus Report</strong></h2><p>Trump said late Thursday that the administration was closely studying the outbreak from the Dutch-flagged cruise ship Hondius, where three passengers have died and several others became infected. “It’s very much, we hope, under control,” Trump said, adding that a full report will be released on Friday.</p><p>The outbreak has triggered six confirmed infections and additional suspected cases aboard the vessel, which had 150 passengers onboard during an Atlantic voyage from Argentina toward Europe. Authorities are still investigating how the virus spread on board.</p><p>Singapore has already isolated two passengers from the ship due to concerns about possible exposure during the trip. The World Health Organization (WHO) also issued an alert on the outbreak, although officials said that the global risk remains low and that hantavirus is less transmissible than COVID-19 or influenza. The virus involved is said to be the Andes strain, one of the few hantavirus variants associated with limited human-to-human transmission.</p><h2 class="st-heading-2"><strong>Moderna Hantavirus Program Back In Focus</strong></h2><p>Moderna is viewed as one of the U.S. government’s key vaccine platforms for outbreaks. Since 2023, the company has worked with Korea University’s Vaccine Innovation Center on an mRNA-based hantavirus vaccine candidate, with preclinical studies earlier this year showing protection against hantavirus infection in mice.</p><p>In 2024, Moderna received a $176 million award backed by the Biomedical Advanced Research and Development Authority (BARDA) in 2024 for the development of mRNA-based pandemic influenza vaccines and outbreak preparedness programs. Moderna’s partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) is also in focus, which previously said mRNA could help shorten vaccine-development timelines to as little as 100 days during outbreaks.</p><h2 class="st-heading-2"><strong>Inovio: Direct Hantavirus Play</strong></h2><p>Inovio, meanwhile, has the clearest hantavirus link among the stocks rallying overnight. The company previously participated in several hantavirus DNA vaccine studies targeting Hantaan, Puumala and Andes hantavirus strains. One National Institute of Allergy and Infectious Diseases-backed study evaluated an Andes virus DNA vaccine to prevent hantavirus pulmonary syndrome, while another U.S. Army-supported study examined mixed hantavirus DNA vaccines.</p><p>While none of Inovio’s hantavirus vaccine programs produced a commercial product, the outbreak revived speculative interest in companies with prior hantavirus research.</p><h2 class="st-heading-2"><strong>NVAX, EBS In Outbreak Spotlight</strong></h2><p>Investors frequently rotate into Novavax during virus headlines due to the company’s vaccine-development platform and history of rapidly developing candidates for pathogens such as Ebola, MERS and Zika. The company’s protein-based nanoparticle platform and Matrix-M adjuvant tech can generate vaccine candidates against emerging infectious diseases, already used in marketed COVID-19 and malaria vaccines.&nbsp;</p><p>Emergent BioSolutions, on the other hand, is often viewed as one of the U.S. government’s primary biodefense and medical-countermeasure contractors during public-health emergencies. The company has existing relationships with BARDA and makes products based on Anthrax, Ebola, smallpox, mpox and viral hemorrhagic fevers. Emergent previously received BARDA task orders for viral hemorrhagic fever therapeutics and has also participated in manufacturing efforts during outbreaks, including Ebola and Zika.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About INO, MRNA, NVAX, EBS?</strong></h2><p>On Stocktwits, retail sentiment for INO and NVAX was ‘extremely bullish’ amid ‘extremely high’ message volume, while MRNA saw ‘bullish’ sentiment with ‘high’ message volume. EBS also recorded ‘extremely bullish’ sentiment, though message volume remained ‘normal.’&nbsp;</p><p>Over the past year, MRNA has surged 102%, followed by EBS up 93% and NVAX higher by 55%, while INO has declined 22%.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-deutsche-bank-stake-boost-ahead-of-earnings/cZX2EhiReXG">SLS Stock Heads For Weekly Win: Deutsche Bank’s Stake Boost Draws Attention Ahead Of Q1 Earnings&nbsp;</a></p>

Trump holds a press conference announcing U.S. Vice President Mike Pence to lead the effort combating the spread of the coronavirus on February 26, 2020. (Photo by Yasin Ozturk/Anadolu Agency via Getty Images)

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally

Inovio is the most direct hantavirus play based on earlier DNA vaccine studies targeting Andes, Hantaan, and Puumala strains.

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.

NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up

Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Current Price	$1.30
Prev Close	$1.36
Open	$1.35
Dividend Yield	0.00%
50-Day Moving Average	$1.37
Beta	1.21
Avg. Volume	3.02M
PE Ratio	-0.76

52-Week High	$2.98
52-Week Low	$1.03
Market Capitalization	$106.52M
EPS (Annual)	-$1.81
Price to Book	14.95
Revenue Per Employee	$583.42

INO
Inovio Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INO News

INOInovio Pharmaceuticals Inc